FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155586983> ?p ?o ?g. }

• W2155586983 abstract "Nucleos(t)ide analogues (NAs) can indirectly restore host immunity against hepatitis B virus (HBV) by inhibiting virus replication. We aimed to investigate whether telbivudine could prevent HBV-related fibrosis progression by their influence on CD4(+) T-cell response.Thirty-six HBeAg-positive patients with chronic hepatitis B (CHB) were enrolled for 52-week telbivudine monotherapy and were followed at treatment week (TW)-0, 4, 12, 24 and 52. By TW-52, the patients were classified into a complete-response group (CR, n = 10) with both negative HBV-DNA and HBeAg, or a part-response group (PR, n = 11) only with negative DNA, or a non-response group (NR, n = 15) still with positive DNA. The peripheral blood mononuclear cells (PBMCs) were prepared for further flow cytometric and real-time PCR analyses, and also for the in vitro experiments with primary hepatic stellate cells (HSCs).Peripherally, all chronic HBV-infected subjects showed the involvement of CD4(+) T-cell responses, among whom the inactive carriers (IC) had Th1 (CD4(+) IFNγ(+) ) dominated, CHB had Th17 (CD4(+) IL-17(+) ) dominated, while the immune tolerant (IT) subjects had Treg (CD4(+) CD25(high) Foxp3(+) ) dominated. Besides, we found the therapeutic responses to telbivudine were especially associated with up-regulation of Th1 and Th17, and down-regulation of Treg. Furthermore, compared to CD4(+) cells from CR, those from NR could in vitro significantly exacerbate cell activation, proliferation and cytokine production of HSCs, which were partly mediated by IL-4 and TGF-β1.Telbivudine might slow down HBV-related liver fibrosis progression by restoring CD4(+) T-cell responses against HBV." @default.
• W2155586983 created "2016-06-24" @default.
• W2155586983 creator A5002622595 @default.
• W2155586983 creator A5003065832 @default.
• W2155586983 creator A5012677271 @default.
• W2155586983 creator A5018411968 @default.
• W2155586983 creator A5046750137 @default.
• W2155586983 creator A5075889094 @default.
• W2155586983 creator A5091729335 @default.
• W2155586983 date "2014-06-02" @default.
• W2155586983 modified "2023-10-15" @default.
• W2155586983 title "Telbivudine therapy may shape CD4+ T-cell response to prevent liver fibrosis in patients with chronic hepatitis B" @default.
• W2155586983 cites W1579017906 @default.
• W2155586983 cites W1936539870 @default.
• W2155586983 cites W1976643312 @default.
• W2155586983 cites W1986904544 @default.
• W2155586983 cites W1991744568 @default.
• W2155586983 cites W1992851412 @default.
• W2155586983 cites W2006178549 @default.
• W2155586983 cites W2008596165 @default.
• W2155586983 cites W2009466011 @default.
• W2155586983 cites W2025335044 @default.
• W2155586983 cites W2025375121 @default.
• W2155586983 cites W2027543203 @default.
• W2155586983 cites W2039929103 @default.
• W2155586983 cites W2043776488 @default.
• W2155586983 cites W2048056516 @default.
• W2155586983 cites W2058636963 @default.
• W2155586983 cites W2062680879 @default.
• W2155586983 cites W2073716326 @default.
• W2155586983 cites W2083672604 @default.
• W2155586983 cites W2095385790 @default.
• W2155586983 cites W2100853445 @default.
• W2155586983 cites W2104193042 @default.
• W2155586983 cites W2108612117 @default.
• W2155586983 cites W2110491264 @default.
• W2155586983 cites W2166849716 @default.
• W2155586983 cites W4211026375 @default.
• W2155586983 cites W4245898328 @default.
• W2155586983 doi "https://doi.org/10.1111/liv.12589" @default.
• W2155586983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24814578" @default.
• W2155586983 hasPublicationYear "2014" @default.
• W2155586983 type Work @default.
• W2155586983 sameAs 2155586983 @default.
• W2155586983 citedByCount "18" @default.
• W2155586983 countsByYear W21555869832015 @default.
• W2155586983 countsByYear W21555869832016 @default.
• W2155586983 countsByYear W21555869832017 @default.
• W2155586983 countsByYear W21555869832018 @default.
• W2155586983 countsByYear W21555869832019 @default.
• W2155586983 countsByYear W21555869832021 @default.
• W2155586983 countsByYear W21555869832022 @default.
• W2155586983 countsByYear W21555869832023 @default.
• W2155586983 crossrefType "journal-article" @default.
• W2155586983 hasAuthorship W2155586983A5002622595 @default.
• W2155586983 hasAuthorship W2155586983A5003065832 @default.
• W2155586983 hasAuthorship W2155586983A5012677271 @default.
• W2155586983 hasAuthorship W2155586983A5018411968 @default.
• W2155586983 hasAuthorship W2155586983A5046750137 @default.
• W2155586983 hasAuthorship W2155586983A5075889094 @default.
• W2155586983 hasAuthorship W2155586983A5091729335 @default.
• W2155586983 hasConcept C126322002 @default.
• W2155586983 hasConcept C137061746 @default.
• W2155586983 hasConcept C202751555 @default.
• W2155586983 hasConcept C203014093 @default.
• W2155586983 hasConcept C2522874641 @default.
• W2155586983 hasConcept C2775940106 @default.
• W2155586983 hasConcept C2776090121 @default.
• W2155586983 hasConcept C2777382497 @default.
• W2155586983 hasConcept C2777410769 @default.
• W2155586983 hasConcept C2777869810 @default.
• W2155586983 hasConcept C2778296632 @default.
• W2155586983 hasConcept C2779727006 @default.
• W2155586983 hasConcept C2780559512 @default.
• W2155586983 hasConcept C2780593183 @default.
• W2155586983 hasConcept C2781144229 @default.
• W2155586983 hasConcept C55493867 @default.
• W2155586983 hasConcept C71924100 @default.
• W2155586983 hasConcept C79484868 @default.
• W2155586983 hasConcept C86803240 @default.
• W2155586983 hasConcept C8891405 @default.
• W2155586983 hasConceptScore W2155586983C126322002 @default.
• W2155586983 hasConceptScore W2155586983C137061746 @default.
• W2155586983 hasConceptScore W2155586983C202751555 @default.
• W2155586983 hasConceptScore W2155586983C203014093 @default.
• W2155586983 hasConceptScore W2155586983C2522874641 @default.
• W2155586983 hasConceptScore W2155586983C2775940106 @default.
• W2155586983 hasConceptScore W2155586983C2776090121 @default.
• W2155586983 hasConceptScore W2155586983C2777382497 @default.
• W2155586983 hasConceptScore W2155586983C2777410769 @default.
• W2155586983 hasConceptScore W2155586983C2777869810 @default.
• W2155586983 hasConceptScore W2155586983C2778296632 @default.
• W2155586983 hasConceptScore W2155586983C2779727006 @default.
• W2155586983 hasConceptScore W2155586983C2780559512 @default.
• W2155586983 hasConceptScore W2155586983C2780593183 @default.
• W2155586983 hasConceptScore W2155586983C2781144229 @default.
• W2155586983 hasConceptScore W2155586983C55493867 @default.
• W2155586983 hasConceptScore W2155586983C71924100 @default.
• W2155586983 hasConceptScore W2155586983C79484868 @default.
• W2155586983 hasConceptScore W2155586983C86803240 @default.

• next